BioCentury
ARTICLE | Company News

Avanir, OptiNose migraine marketing deal

July 3, 2013 1:01 AM UTC

OptiNose Inc. (Yardley, Pa.) granted Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) exclusive North American rights to commercialize OptiNose's acute migraine product, OptiNose sumatriptan (AVP-825). OptiN...